event tracking

International Linked Clinical Trials (iLCT)

28 results.

February 12, 2020 $4.5 million co-funding agreement for Parkinson’s research announced

LONDON (Feb. 13, 2020) — The Cure Parkinson’s Trust (CPT) and Van Andel Institute (VAI) are delighted to announce a new three-year co-funding agreement that…

January 12, 2020 Phase II clinical trial of respiratory drug for treatment of Parkinson's disease reveals promising results

The Cure Parkinson's Trust (CPT) is delighted to announce the publication of the results of a Phase II clinical trial evaluating ambroxol as a…

October 17, 2019 How Van Andel Institute supports clinical trials through collaboration and connection

Institute serves as a connector that fosters discovery of potential new treatments

Clinical trials can be a bastion of hope for people living…

January 29, 2019 Australian Government invests in innovative genomic testing in Linked Clinical Trials program

This story originally appeared on The Cure Parkinson’s Trust website. To learn more, click here.

 

It was announced today that the Australian Parkinson's…

October 10, 2018 ICYMI: Three big takeaways from Grand Challenges in Parkinson’s Disease

Did you miss Grand Challenges in Parkinson’s Disease and Rallying to the Challenge? Don’t worry. We have you covered.

Just over a week ago, the…

June 13, 2018 From discovery to medicine
Part three: What we’re doing to move lab discoveries into the clinic

In the past few weeks, VAI Voice has discussed what it takes to translate a promising laboratory discovery into a life-changing, approved treatment. In our…

June 7, 2018 From discovery to medicine
Part two: Before a new medication can be used in patients, it must go through a gauntlet of tests to ensure it is safe and effective

In the second installment in our multi-part series on how a new medication moves from the lab to the doctor’s office, we take a look…

VAI DEFAULT HEADER
August 2, 2017 Promising results from study of type 2 diabetes drug in treatment of Parkinson’s disease

Evidence continues to mount that a newer class of anti-diabetic drugs called incretin mimetics, or glucagon-like peptide-1 receptor agonists, could slow…